Related Experiment Videos
Topical tacrolimus therapy for pyoderma gangrenosum.
Takashi Chiba1, Iwao Isomura, Akiko Suzuki
1Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
The Journal of Dermatology
|May 3, 2005
Summary
Pyoderma gangrenosum (PG) is a chronic neutrophilic disorder. Topical tacrolimus effectively treated a steroid-resistant PG case, promoting ulcer healing and enabling corticosteroid dose reduction.
Area of Science:
- Dermatology
- Immunology
Background:
- Pyoderma gangrenosum (PG) is a rare, chronic neutrophilic inflammatory skin disease.
- Management often involves immunosuppressive agents, with corticosteroids as first-line therapy.
- Systemic steroids are not always effective, necessitating alternative treatments.
Observation:
- A 54-year-old male patient presented with a 14-year history of recalcitrant pyoderma gangrenosum.
- Necrotic ulcers on the right leg were refractory to high-dose oral prednisolone.
- The patient had failed to respond to conventional systemic steroid therapy.
Findings:
- Topical tacrolimus applied to ulcer borders demonstrated significant efficacy.
- Accelerated epithelization of pyoderma gangrenosum ulcers was observed.
- Successful reduction of oral prednisolone dosage was achieved concurrently.
Implications:
- Topical tacrolimus presents a potential alternative treatment for steroid-resistant pyoderma gangrenosum.
- This approach may offer a localized immunosuppressive strategy with reduced systemic side effects.
- Further research into topical tacrolimus for pyoderma gangrenosum is warranted.